Breakthrough drug for heart failure now available in the UK
Novartis drug Entresto™ (sacubitril/valsartan) approved for use in adults with symptomatic chronic heart failure with reduced ejection fraction reduces mortality risk compared with current treatment according to study
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cardiovascular medicine Legislation & regulation Patient care British Society for Heart Failure chronic heart failure ejection fraction Entresto HFrEF Latest News mortality risk PARADIGM Source Type: news
More News: Cardiology | Cardiovascular | Diovan | Drugs & Pharmacology | Heart | Heart Failure | Study